Detalles de la búsqueda
1.
Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study.
Int J Gynecol Cancer
; 33(11): 1750-1756, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931975
2.
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Gynecol Oncol
; 156(3): 545-551, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932108
3.
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
Ann Surg Oncol
; 26(9): 2943-2951, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31243666
4.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecol Oncol
; 153(3): 541-548, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005287
5.
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clin Trials
; 16(5): 502-511, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31347385
6.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer
; 119(9): 1075-1085, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353045
7.
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 387(10023): 1066-1074, 2016 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27025186
8.
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
Int J Gynecol Cancer
; 27(6): 1118-1122, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28333841
9.
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Oncol
; 17(11): 1579-1589, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27617661
10.
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Cancer
; 122(12): 1844-52, 2016 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27062051
11.
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Br J Cancer
; 115(11): 1313-1320, 2016 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27824811
12.
Patient Support Groups Identifying Clinical Equipoise in UK Gynaecological Oncology Surgeons as the Basis for Trials in Ultraradical Surgery for Advanced Ovarian Cancer.
Int J Gynecol Cancer
; 26(1): 91-4, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26512783
13.
Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.
Arch Gynecol Obstet
; 294(3): 607-14, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27040418
14.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol
; 16(8): 928-36, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26115797
15.
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Oncologist
; 20(4): 368-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25795637
16.
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
N Engl J Med
; 366(15): 1382-92, 2012 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22452356
17.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Lancet Oncol
; 15(8): 852-61, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24882434
18.
Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer.
Int J Gynecol Cancer
; 24(4): 676-81, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24651630
19.
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Int J Gynecol Cancer
; 24(3): 468-77, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24557434
20.
Current controversies in the management of germ cell ovarian tumours.
Curr Opin Oncol
; 25(5): 539-45, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23942298